Literature DB >> 29858277

Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis.

Helen L Petsky1, Chris J Cates2, Kayleigh M Kew3, Anne B Chang4,5.   

Abstract

BACKGROUND: Asthma guidelines guide health practitioners to adjust treatments to the minimum level required for asthma control. As many people with asthma have an eosinophilic endotype, tailoring asthma medications based on airway eosinophilic levels (sputum eosinophils or exhaled nitric oxide, FeNO) may improve asthma outcomes.
OBJECTIVE: To synthesise the evidence from our updated Cochrane systematic reviews, for tailoring asthma medication based on eosinophilic inflammatory markers (sputum analysis and FeNO) for improving asthma-related outcomes in children and adults. DATA SOURCES: Cochrane reviews with standardised searches up to February 2017. STUDY SELECTION: The Cochrane reviews included randomised controlled comparisons of tailoring asthma medications based on sputum analysis or FeNO compared with controls (primarily clinical symptoms and/or spirometry/peak flow).
RESULTS: The 16 included studies of FeNO-based management (seven in adults) and 6 of sputum-based management (five in adults) were clinically heterogeneous. On follow-up, participants randomised to the sputum eosinophils strategy (compared with controls) were significantly less likely to have exacerbations (62 vs 82/100 participants with ≥1 exacerbation; OR 0.36, 95% CI 0.21 to 0.62). For the FeNO strategy, the respective numbers were adults OR 0.60 (95% CI 0.43 to 0.84) and children 0.58 (95% CI 0.45 to 0.75). However, there were no significant group differences for either strategy on daily inhaled corticosteroids dose (at end of study), asthma control or lung function.
CONCLUSION: Adjusting treatment based on airway eosinophilic markers reduced the likelihood of asthma exacerbations but had no significant impact on asthma control or lung function. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  asthma; exhaled airway markers; paediatric asthma; pulmonary eosinophilia

Mesh:

Substances:

Year:  2018        PMID: 29858277     DOI: 10.1136/thoraxjnl-2018-211540

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  21 in total

Review 1.  Resolution of allergic asthma.

Authors:  Susetta Finotto
Journal:  Semin Immunopathol       Date:  2019-11-08       Impact factor: 9.623

2.  Allergic Endotypes and Phenotypes of Asthma.

Authors:  Nicole Akar-Ghibril; Thomas Casale; Adnan Custovic; Wanda Phipatanakul
Journal:  J Allergy Clin Immunol Pract       Date:  2020-02

3.  Treatment options in type-2 low asthma.

Authors:  Timothy S C Hinks; Stewart J Levine; Guy G Brusselle
Journal:  Eur Respir J       Date:  2021-01-21       Impact factor: 16.671

Review 4.  Asthma in the Primary Care Setting.

Authors:  Tianshi David Wu; Emily P Brigham; Meredith C McCormack
Journal:  Med Clin North Am       Date:  2019-05       Impact factor: 5.456

5.  Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use.

Authors:  Natalia Hernandez-Pacheco; Susanne J Vijverberg; Esther Herrera-Luis; Jiang Li; Yang Yie Sio; Raquel Granell; Almudena Corrales; Cyrielle Maroteau; Ryan Lethem; Javier Perez-Garcia; Niloufar Farzan; Katja Repnik; Mario Gorenjak; Patricia Soares; Leila Karimi; Maximilian Schieck; Lina Pérez-Méndez; Vojko Berce; Roger Tavendale; Celeste Eng; Olaia Sardon; Inger Kull; Somnath Mukhopadhyay; Munir Pirmohamed; Katia M C Verhamme; Esteban G Burchard; Michael Kabesch; Daniel B Hawcutt; Erik Melén; Uroš Potočnik; Fook Tim Chew; Kelan G Tantisira; Steve Turner; Colin N Palmer; Carlos Flores; Maria Pino-Yanes; Anke H Maitland-van der Zee
Journal:  Eur Respir J       Date:  2021-05-13       Impact factor: 16.671

Review 6.  Addressing the risk domain in the long-term management of pediatric asthma.

Authors:  Eckard Hamelmann; Erika von Mutius; Andrew Bush; Stanley J Szefler
Journal:  Pediatr Allergy Immunol       Date:  2019-12-11       Impact factor: 6.377

Review 7.  Severe Asthma-Perspectives From Adult and Pediatric Pulmonology.

Authors:  Louise Fleming; Liam Heaney
Journal:  Front Pediatr       Date:  2019-10-09       Impact factor: 3.418

8.  Modern Inflammatory Phenotyping of Asthma. Breathomics Is Here to Stay.

Authors:  Peter J Sterk
Journal:  Am J Respir Crit Care Med       Date:  2019-08-15       Impact factor: 21.405

9.  Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST).

Authors:  Sonali Bose; Christian Bime; Robert J Henderson; Kathryn V Blake; Mario Castro; Emily DiMango; Nicola A Hanania; Janet T Holbrook; Charles G Irvin; Monica Kraft; Stephen P Peters; Joan Reibman; Elizabeth A Sugar; Kaharu Sumino; Robert A Wise; Linda Rogers
Journal:  J Allergy Clin Immunol Pract       Date:  2020-07-18

Review 10.  Improving adherence in chronic airways disease: are we doing it wrongly?

Authors:  Gráinne d'Ancona; John Weinman
Journal:  Breathe (Sheff)       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.